Speaking of Regeneron, they are not enrolling very sick people
Regeneron to stop enrolling very sick COVID-19 patients in antibody trial
By Ankur Banerjee
(Reuters) - Regeneron Pharmaceuticals said on Friday it would stop enrolling patients receiving advanced COVID-19 care in a trial testing its experimental antibody treatment in hospitalized patients, based on the recommendation of an independent safety board.
The recommendation was based on a potential safety signal and an unfavorable risk-benefit profile at this time, the company said. Rival Eli Lilly & Co stopped enrolling such patients based on a similar suggestion earlier this week.
"It appears a trend is emerging in the class, and it may be that neutralizing antibodies simply do not work and/or are not safe in this (hospitalized) population," JP Morgan analyst Cory Kasimov said in a note.
Both treatments belong to a class of drugs known as monoclonal antibodies. Regeneron's drug, which was administered to U.S. President Donald Trump before he was hospitalized, was credited by him for his recovery from COVID-19.
Regeneron continues to enroll other types of patients for trials and its enrollment in non-hospitalized patients as well as hospitalized patients requiring either no or a low level of oxygen has been backed by the independent data monitoring committee.
https://news.yahoo.com/regeneron-stop-enrolling-very-sick-151542504.html